AstraZeneca's hopes for baxdrostat are high, as in early 2023 it acquired the drug by purchasing its developer -- biotech ...

AstraZeneca's aldosterone synthase inhibitor baxdrostat reduced blood pressure by 14 mmHg over 12 weeks, the pharma has said ...

Shares in AstraZeneca rose past their September 2024 peak on Tuesday, hitting a fresh record high and cementing the company's ...

AstraZeneca will market the therapy as Lokelma, while Sun Pharma will promote and distribute it as Gimliand. AstraZeneca will ...

Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.

AstraZeneca is the stock to beat in the United Kingdom. The global pharmaceutical company saw its stock rise to its all-time ...

The combined rate of heart attack, stroke, bleeding complications or death was 16.6% in the ticagrelor group and 14.2% in the ...

CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere ...

Britain's FTSE 100 closed at a record high for the second straight session on Tuesday, as weak UK labour market data boosted ...

AstraZeneca said work on its new plant north of Charlottesville will begin immediately and be open within five years.

London's export-focused FTSE 100 rose to a new intraday record peak on Tuesday, buoyed by a weakening pound after economic ...